NCT04541225 - Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

GliomaGlioma, MalignantGlioma, MixedGlial Cell TumorsBreast CancerBreast CarcinomaCancer of BreastCancer of the BreastBreast TumorMalignant Tumor of BreastAdvanced Breast CancerAdvanced Breast CarcinomaMetastatic Breast CancerMetastatic Breast CarcinomaProstate CancerProstatic CancerCancer of ProstateCancer of the ProstateProstate NeoplasmCastrate Resistant Prostate CancerCastration-resistant Prostate CancerCastration Resistant Prostatic NeoplasmsGlioblastomaRecurrent Glioblastoma

Interventions

DRUG

NUV-422

NUV-422 is an investigational drug for oral dosing.

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

22031

Virginia Cancer Specialists, Fairfax

28078

Carolina BioOncology Institute, Huntersville

29605

Prisma Health Cancer Institute, Greenville

33176

Miami Cancer Institute, Miami

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology, Tyler

77030

The University of Texas MD Anderson Cancer Center, Houston

78705

Texas Oncology P.A. Austin, Austin

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

85711

Arizona Oncology Associates, Tucson

02215

Dana-Farber Cancer Institute, Boston